Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626
Phase of Trial: Phase I
Latest Information Update: 29 Feb 2016
At a glance
- Drugs LY 3202626 (Primary) ; Itraconazole
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.